Automera
PrivateLast Round
Series A
Sep 27, 2023
Total Funding Raised
$16M
Company Overview
Automera is a biotechnology company that develops autophagy-targeting chimera small molecules (AUTACs) for targeted protein degradation to treat cancer, inflammation, and central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Automera Comparables
Compare Automera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PAQ Therapeutics | 91% | |
| AUTOTAC Bio | 90% | |
| Casma Therapeutics | 86% | |
Automera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 27, 2023 |
Automera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Accelerator Life Science Partners | Series A |
| Xora Innovation | Series A |
| ClavystBio | Series A |
| EDBI | Series A |
Automera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Automera's valuation, stock price, and market status.